A Pivotal Trial to Establish the Efficacy and Long-term Safety of the Parachute Implant System

Candidates for this study must meet ALL of the following inclusion criteria: Clinical Inclusion Criteria: * Age ≥ 18 and ≤ 79 years. * Body Mass Index (BMI) ≤ 40. * Symptomatic ischemic heart failure (New York Heart Association (NYHA) Class III or "ambulatory" Class IV as determined through the use of the SAS) post Myocardial Infarction (MI) in the Left Anterior Descending (LAD) territory at least 60 days prior to enrollment. * Patient is not hospitalized at the time of enrollment. * Receiving appropriate medical treatment for heart failure according to the current American College of Cardiology (ACC)/American Heart Association (AHA) Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult during the three months prior to enrollment. * The patient or the patient's legal representative has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent as approved by the Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site. * The patient and the treating physician agree that the patient will return for all required post-procedure follow-up visits. Inclusion Criteria based on Imaging: * 15% ≤ Left Ventricular Ejection Fraction (LVEF) ≤ 35% by Transthoracic Echocardiogram (TTE). * Post LV MI structural heart dysfunction represented by LV wall motion abnormality (WMA) by TTE. * Left ventricle must have appropriate anatomy (size and morphology) for implant placement u…